stockportfolio.pro
Stocks / CVS vs VRTX
CVS vs VRTX
CVS Health Corporation and Vertex Pharmaceuticals Incorporated side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| CVS Health Corporation (CVS) | Vertex Pharmaceuticals Incorporated (VRTX) | |
|---|---|---|
| Market cap | $128.5B | $114.3B |
| Revenue (latest FY) | $402.07B | $12.00B |
| Net income (latest FY) | $1.77B | $3.95B |
| Revenue growth (5y CAGR) | 8.4% | 14.1% |
| Net margin | 0.4% | 32.9% |
| Return on equity | 2.4% | 21.2% |
| P/E ratio | 44.2 | 26.7 |
| Dividend yield | 2.6% | — |
| Profitable years (of last 10) | 9 | 8 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CVS — free Open VRTX — freeFrequently asked questions
Which is bigger, CVS or VRTX?
CVS Health Corporation is larger by market capitalization — $128.5B versus $114.3B.
Which grows faster, CVS or VRTX?
Over the last five fiscal years, Vertex Pharmaceuticals Incorporated grew revenue faster — 14.1%/yr versus 8.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.